Life science leader executive editor blog Life science leader executive editor blog

Durable Take-Homes from DCAT Week 15 — And Our Annual CMO Awards Celebration
Durable Take-Homes from DCAT Week 15 — And Our Annual CMO Awards Celebration It is now weeks since I returned home from this year’s DCAT Week conference in New York City, and the delay has benefitted my perspective, testing each “take-home” for durability of importance over time. The important links remain, while the non-essential ones slough off like falling leaves.  Continue Reading...
Valor For Invention
Valor For Invention A lot of discussion at Biocom’s Global Partnering Conference about large companies’ continuing inability to deal with risk. I’m not reflecting public perception here, but the opinions of people in the industry, in companies large and small.  Continue Reading...
Pharma — Frozen in Place or Running from the Past?
Pharma — Frozen in Place or Running from the Past? We editors have debates about whether Pfizer is pharma or “biopharma.” After all, what self-respecting Big Pharma would risk being caught dead these days with no biotech-based products? Does that mean they have all outgrown the pharma label?  Continue Reading...
Bio By The Bay — Science Means Business
Bio By The Bay — Science Means Business Somebody better teach these start-up executives how to run a company — and FAST! No clearer rationale was needed for the San Francisco Bay Area industry group, the BayBio Institute, to get moving with its FAST (Fellows All-Star Team) mentoring program to serve the leaders of BayBio’s smallest member companies, or Fellows.  Continue Reading...
A Braver Agenda - Reflections On The BIO Investor Forum 2014
A Braver Agenda - Reflections On The BIO Investor Forum 2014 The BIO Investor Forum, October 7 and 8, in San Francisco, fourteen pages of tweets, a sheaf of business cards, reams of notes, and memorable moments and as almost everywhere else, the subject of Ebola frequently surfaced. Was it just on our minds because it was threatening “our people” for the first time? Yes. But more on Ebola later.  Continue Reading...
Taxes At Work: The Federal Government Gives A Boost To Life Science Start-ups
Taxes At Work: The Federal Government Gives A Boost To Life Science Start-ups An Interview with Michael Weingarten, Head of the NCI SBIR Development Center, and Lean Launchpad’s Steve Blank, NIH Business Mentor.  Continue Reading...
Leading By Following — BayBio’s Gail Maderis
Leading By Following — BayBio’s Gail Maderis BayBio’s survey and white paper, “Successful Public-Private Partnerships,” was the wellspring of our four-part series on best practices for collaborations between life science companies and patient/disease foundations in drug development. Here the head of the San Francisco Bay area biotech-industry association offers perspectives on the survey’s origin, implementation, and results.   Continue Reading...
Tear Down These Walls — Overcoming Global Barriers To BioPharma Access
Tear Down These Walls — Overcoming Global Barriers To BioPharma Access People from every region of Earth work, travel, mix, and mingle with each other, more or less harmoniously, all joined in the industry’s common identity and purpose. Our motivations may be as diverse as our geographies — some seeking fortune, others fidelity to humanitarian ideals, and the rest all shades in between — but we all gain something immensely valuable from the sum of our parts.  Continue Reading...
Clinical Trial Upgrades — A Critical Path to Innovative Consortia
Clinical Trial Upgrades — A Critical Path to Innovative Consortia At the 2014 BIO International Convention in June, I spoke with Martha Brumfield, President and CEO of the Critical Path Institute (C-Path), and Diane Stephenson, Executive Director of C-Path’s Coalition Against Major Diseases. C-Path is a non-profit organization working with the FDA and the EMA in forming government-industry consortia that create new universal biomarkers and clinical-trial simulation software tools to improve the speed and ...  Continue Reading...
A Tale of Two Confabs
A Tale of Two Confabs I returned from the ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago, I headed for the annual BIO International Convention in San Diego. But at BIO, ASCO was still on my mind, for it was among the most extraordinary of events I, and surely many others, have ever attended.   Continue Reading...

BE A CONTRIBUTOR